Trial Profile
A Single-Centre, Placebo-Controlled, Randomized, Double-Blind Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AZD3241 Following Administration of Single Ascending (Part A) and Fractionated Ascending (Part B) Oral Doses to Young Healthy Volunteers
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 26 Aug 2008
Price :
$35
*
At a glance
- Drugs Verdiperstat (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions
- 26 Aug 2008 New trial record.